Entrada Therapeutics Inc (NAS:TRDA)
$ 5.84 -0.20 (-3.31%) Market Cap: 226.91 Mil Enterprise Value: 195.93 Mil PE Ratio: 0 PB Ratio: 0.84 GF Score: 35/100

Entrada Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 14, 2026 / 11:45 PM GMT
Release Date Price: $10.58 (+1.15%)


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TRDA.OQ - Entrada Therapeutics Inc
Entrada Therapeutics Inc at JPMorgan Healthcare Conference
Jan 14, 2026 / 11:45PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon everyone. My name is Shrishmatha Roy. I'm an associate on the healthcare investment banking team here at JP Morgan. On behalf of JPMorgan, first of all, welcome, thank you so much for taking the time to attend the conference. It's been a great conference so far and, to continue the festivities rolling, I'm thrilled to introduce Entrada Therapeutics and for their company presentation today. A little bit about Entrada before we get started. Entrada is focused on treating devastating diseases with intracellular targets. Last week, Entrada highlighted important progress across its EEV portfolio for neuromuscular and ocular diseases. The company is advancing multiple clinical programs in people living with
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot